医学
急性肾损伤
血清氯化物
肾脏替代疗法
逻辑回归
内科学
死亡率
人口
回顾性队列研究
队列研究
氯化物
材料科学
环境卫生
冶金
作者
Rugang Li,Yuxuan Chen,Qihong Liang,Shi-Yu Zhou,Shengli An
出处
期刊:Minerva Anestesiologica
[Edizioni Minerva Medica]
日期:2023-03-01
卷期号:89 (3)
被引量:1
标识
DOI:10.23736/s0375-9393.22.16686-1
摘要
BACKGROUND: The association between baseline serum chloride levels and mortality in patients with severe acute kidney injury (AKI) is unknown. Our aim was to investigate the relationship between baseline blood chloride levels and 28-day mortality in patients with AKI admitted to the ICU and to detect possible effect modifiers in this population.METHODS: AKI patients with severe critical illness were extracted from the MIMIC-IV. During ICU admission, chloride levels were measured for the first time. Our primary outcome was 28-day mortality in patients with AKI after 24 hours in the ICU. Multivariable logistic regression was used to examine the association between three groups of chloride levels and 28-day mortality, and logistic regression with restricted cubic spline was applied to detect the non-linear trendy.RESULTS: A total of 24,166 patients with critically ill AKI were included in this retrospective cohort study. The total 28-day mortality rate in the ICU was 15.9%. Overall, there was a U-shaped relationship between baseline serum chloride levels and 28-day mortality (non-linear P<0.001). Accordingly, patients with low serum chloride (<96 mEq/L) had a significantly increased risk of death compared to patients with normal serum chloride (96-108 meq/L) (adjusted OR=1.94, 95% CI: 1.68-2.24, P<0.001). None of the variables, including age, gender, 24-hour fluid intake, continuous renal replacement therapy, ventilation, Atrial fibrillation, Sequential Organ Failure Assessment score, whether to measure lactate and AKI stage, significantly modified the association between lower chloride levels and 28-day mortality.CONCLUSIONS: Low serum chloride levels at baseline were associated with death at 28 days in intensive illnesses with AKI.
科研通智能强力驱动
Strongly Powered by AbleSci AI